Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 114
Filtrar
1.
MMWR Morb Mortal Wkly Rep ; 71(48): 1517-1521, 2022 Dec 02.
Artigo em Inglês | MEDLINE | ID: mdl-36454695

RESUMO

In July 2021, the Virginia Department of Health notified CDC of a cluster of eight invasive infections with Burkholderia stabilis, a bacterium in the Burkholderia cepacia complex (BCC), among hospitalized patients at hospital A. Most patients had undergone ultrasound-guided procedures during their admission. Culture of MediChoice M500812 nonsterile ultrasound gel used in hospital A revealed contamination of unopened product with B. stabilis that matched the whole genome sequencing (WGS) of B. stabilis strains found among patients. CDC and hospital A, in collaboration with partner health care facilities, state and local health departments, and the Food and Drug Administration (FDA), identified 119 B. stabilis infections in 10 U.S. states, leading to the national recall of all ultrasound gel products produced by Eco-Med Pharmaceutical (Eco-Med), the manufacturer of MediChoice M500812. Additional investigation of health care facility practices revealed frequent use of nonsterile ultrasound gel to assist with visualization in preparation for or during invasive, percutaneous procedures (e.g., intravenous catheter insertion). This practice could have allowed introduction of contaminated ultrasound gel into sterile body sites when gel and associated viable bacteria were not completely removed from skin, leading to invasive infections. This outbreak highlights the importance of appropriate use of ultrasound gel within health care settings to help prevent patient infections, including the use of only sterile, single-use ultrasound gel for ultrasonography when subsequent percutaneous procedures might be performed.


Assuntos
Infecções por Burkholderia , Surtos de Doenças , Contaminação de Equipamentos , Instalações de Saúde , Humanos , Contaminação de Medicamentos , Ultrassonografia , Estados Unidos/epidemiologia , Géis , Infecções por Burkholderia/epidemiologia , Infecções por Burkholderia/etiologia
2.
Int J Infect Dis ; 121: 152-156, 2022 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-35562041

RESUMO

OBJECTIVES: Burkholderia gladioli has been associated with infections in patients with cystic fibrosis, chronic granulomatous disease, and other immunocompromising conditions. The aim of this study was to better depict the outbreak of healthcare-associated bacteremia caused by B. gladioli due to exposure to contaminated multidose vials with saline solutions. METHODS: An environmental and epidemiologic investigation was conducted by the Infection Prevention and Control Team (IPCT) to identify the source of the outbreak in three Croatian hospitals. RESULTS: During a 3-month period, 13 B. gladioli bacteremia episodes were identified in 10 patients in three Croatian hospitals. At the time of the outbreak, all three hospitals used saline products from the same manufacturer. Two 100-ml multidose vials with saline solutions and needleless dispensing pins were positive for B. gladioli. All 13 bacteremia isolates and two isolates from the saline showed the same antimicrobial susceptibility patterns and pulsed-field gel electrophoresis profile, demonstrating clonal relatedness. CONCLUSION: When an environmental pathogen causes an outbreak, contamination of intravenous products must be considered. Close communication between the local IPCT and the National Hospital Infection Control Advisory Committee is essential to conduct a prompt and thorough investigation and find the source of the outbreak.


Assuntos
Bacteriemia , Infecções por Burkholderia , Burkholderia gladioli , Infecção Hospitalar , Bacteriemia/epidemiologia , Bacteriemia/prevenção & controle , Infecções por Burkholderia/epidemiologia , Infecções por Burkholderia/etiologia , Infecções por Burkholderia/prevenção & controle , Croácia/epidemiologia , Infecção Hospitalar/epidemiologia , Infecção Hospitalar/prevenção & controle , Atenção à Saúde , Surtos de Doenças , Hospitais , Humanos , Solução Salina
3.
Antimicrob Resist Infect Control ; 10(1): 143, 2021 10 10.
Artigo em Inglês | MEDLINE | ID: mdl-34629114

RESUMO

BACKGROUND: We report a nosocomial outbreak caused by Burkholderia cepacia that occurred among six patients admitted in the medical and surgical intensive care unit between 04 March 2019 and 02 April 2019 in Istanbul, Turkey. METHODS: The outbreak investigation was launched on 11 March 2019 five days after the detection of B. cepacia in four different patients. We defined potential reservoirs and started environmental screening. We sampled the liquid solutions used in patient care activities. Pulse-field gel electrophoresis (PFGE) was performed to determine the genetic relatedness of environmental and patient samples. RESULTS: Burkholderia cepacia was isolated in tracheal aspiration cultures of six patients. Three out of six patients developed healthcare-associated pneumoniae due to B. cepacia. Environmental cultures in the ICUs revealed B. cepacia growth in 2% chlorhexidine-gluconate mouthwash solution that been used in the colonized patients as well as in samples obtained from the unused products. PFGE revealed the patient and a specific batch of chlorhexidine mouthwash solution samples had a 96% similarity. CONCLUSION: Contamination of medical solutions used in critical patient care could cause outbreaks and should be detected early by infection control teams.


Assuntos
Infecções por Burkholderia/epidemiologia , Infecções por Burkholderia/etiologia , Infecção Hospitalar/epidemiologia , Infecção Hospitalar/etiologia , Surtos de Doenças , Antissépticos Bucais/efeitos adversos , Anti-Infecciosos Locais , Clorexidina , Contaminação de Medicamentos , Eletroforese em Gel de Campo Pulsado , Humanos , Pneumonia/microbiologia , Centros de Atenção Terciária , Traqueia/microbiologia , Turquia/epidemiologia
4.
Antimicrob Resist Infect Control ; 10(1): 1, 2021 01 06.
Artigo em Inglês | MEDLINE | ID: mdl-33407871

RESUMO

BACKGROUND: This report describes an outbreak of 71 patients developed B. cepacia urinary tract infection (UTI) by contaminated single-use anesthetic gel. METHODS: Epidemiological investigation of patients with B. cepacia-positive urine or blood samples between March 19, 2018 and Novemeber 15, 2018 was conducted to identify the source of infection. Microbiological samples from hospital surfaces, endoscopes, disposable items, and the hands of staff were tested for B. cepacia contamination. Pulsed-field gel electrophoresis (PFGE) was used to compare homology in B. cepacia isolates. RESULTS: During the outbreak, nosocomial B. cepacia UTI was confirmed in 71 patients. Epidemiological investigation showed that 66 patients underwent invasive urological diagnosis and treatment, while the remaining five patients underwent bedside indwelling catheterization, with all patients exposed to single-use anesthetic gel. All batches of anesthetic gel were recalled and the outbreak abated. Overall, 155 samples were collected from environmental surfaces and disposable items, and B. cepacia contamination was confirmed in samples from one used cystoscope and three anesthetic gels from the same batch. PFGE showed homology between 17 out of 20 B. cepacia isolates from patients and three isolates from the contaminated anesthetic gel. All patients achieved cure. CONCLUSION: Contaminated single-use anesthetic gel was confirmed as the source of the B. cepacia outbreak, with infection occurring during invasive urological diagnostic and treatments. Thus, investigations of nosocomial outbreaks of B. cepacia infection should consider contamination of diagnostic and treatment items used in infected patients.


Assuntos
Anestésicos , Infecções por Burkholderia/tratamento farmacológico , Infecção Hospitalar/etiologia , Contaminação de Medicamentos , Infecções Urinárias/etiologia , Infecções por Burkholderia/etiologia , China , Infecção Hospitalar/tratamento farmacológico , Surtos de Doenças , Eletroforese em Gel de Campo Pulsado , Feminino , Géis , Hospitais de Ensino , Humanos , Controle de Infecções , Masculino , Pessoa de Meia-Idade , Polissacarídeos Bacterianos , Centros de Atenção Terciária , Infecções Urinárias/tratamento farmacológico
5.
Ann Clin Microbiol Antimicrob ; 20(1): 6, 2021 Jan 07.
Artigo em Inglês | MEDLINE | ID: mdl-33413453

RESUMO

BACKGROUND: Burkholderia cepacia, an opportunistic pathogen mainly affecting patients with cystic fibrosis or immunocompromised, has rarely been documented as a cause of corneal infection. The clinical and microbiological profiles of B. cepacia keratitis are reported herein. METHODS: We retrospectively reviewed the medical record of 17 patients with culture-proven B. cepacia keratitis, treated between 2000 and 2019 at Chang Gung Memorial Hospital, Taiwan. Our data included predisposing factors, clinical presentations, treatments, and visual outcomes of B. cepacia keratitis as well as the drug susceptibility of the causative agent. RESULTS: The most common predisposing factor for B. cepacia keratitis was preexisting ocular disease (seven, 41.2%), particularly herpetic keratitis (five). Polymicrobial infection was detected in seven (41.2%) eyes. All B. cepacia isolates were susceptible to ceftazidime. Main medical treatments included levofloxacin or ceftazidime. Surgical treatment was required in five (29.4%) patients. Only four (23.5%) patients exhibited final visual acuity better than 20/200. CONCLUSIONS: B. cepacia keratitis primarily affects patients with preexisting ocular disease, particularly herpetic keratitis, and responds well to ceftazidime or fluoroquinolones. However, the visual outcomes are generally poor.


Assuntos
Infecções por Burkholderia/tratamento farmacológico , Burkholderia cepacia , Ceratite/tratamento farmacológico , Adulto , Idoso , Idoso de 80 Anos ou mais , Infecções por Burkholderia/etiologia , Infecções por Burkholderia/microbiologia , Burkholderia cepacia/efeitos dos fármacos , Farmacorresistência Bacteriana Múltipla , Feminino , Humanos , Ceratite/etiologia , Ceratite/microbiologia , Masculino , Pessoa de Meia-Idade , Estudos Retrospectivos , Acuidade Visual
6.
Am J Trop Med Hyg ; 104(3): 848-853, 2020 12 14.
Artigo em Inglês | MEDLINE | ID: mdl-33319730

RESUMO

Patients undergoing hemodialysis are at an increased risk for bloodstream infections (BSIs). Infection usually occurs because of contamination of water supply, water treatment, distribution systems, or reprocessing dialyzers. Here, we report an outbreak of BSIs caused by Stenotrophomonas maltophilia (n = 21) and Burkholderia cepacia (n = 22) among dialyzed patients at a large hemodialysis center in Brazil. Overall, three patients died (7%), two of which had bacteremia caused by S. maltophilia and the other had a B. cepacia infection. We collected water samples from different points of the hemodialysis system for culture and typing. Genetic patterns were identified through polymerase chain reaction-random amplified polymorphic DNA (PCR-RAPD) and pulsed-field gel electrophoresis. The same genotypes of S. maltophilia and B. cepacia recovered from blood cultures were found in dialysis water. Also, multiple genetic profiles were identified among water isolates, suggesting heavy contamination. Bacteremia cases persisted even after implementing standard control measures, which led us to believe that the piping system was contaminated with microbial biofilms. Soon after we changed the entire plumbing system, reported cases dropped back to the number typically expected, and the outbreak came to an end.


Assuntos
Infecções por Burkholderia/epidemiologia , Burkholderia cepacia/isolamento & purificação , Surtos de Doenças , Infecções por Bactérias Gram-Negativas/epidemiologia , Diálise Renal/efeitos adversos , Stenotrophomonas maltophilia/isolamento & purificação , Adulto , Idoso , Idoso de 80 Anos ou mais , Brasil/epidemiologia , Infecções por Burkholderia/etiologia , Infecções por Burkholderia/prevenção & controle , Burkholderia cepacia/classificação , Burkholderia cepacia/genética , Desinfecção/métodos , Feminino , Infecções por Bactérias Gram-Negativas/etiologia , Infecções por Bactérias Gram-Negativas/prevenção & controle , Humanos , Masculino , Pessoa de Meia-Idade , Diálise Renal/normas , Sepse/epidemiologia , Sepse/etiologia , Sepse/prevenção & controle , Stenotrophomonas maltophilia/classificação , Stenotrophomonas maltophilia/genética
8.
Eur J Clin Microbiol Infect Dis ; 39(11): 2057-2064, 2020 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-32583228

RESUMO

Burkholderia cepacia complex (BCC) is an emerging pathogen of nosocomial infection in chronic or critically ill patients without cystic fibrosis (CF). The objective was to evaluate the management and outcomes of BCC bacteremia in patients without CF. We conducted a retrospective study of non-CF adult patients with BCC bacteremia between January 1997 and December 2016 at 4 tertiary hospitals in South Korea. A total of 216 non-CF patients with BCC bacteremia were identified. Most cases were hospital-acquired (79.2%), and the most common source was a central venous catheter (CVC) (42.1%). The rates of susceptibility to trimethoprim-sulfamethoxazole and piperacillin-tazobactam of BCC isolates were high as 92.8% and 90.3%, respectively. The rates of susceptibility to ceftazidime, meropenem, and levofloxacin were 75.5%, 72.3%, and 64.1%, respectively. The 14-day, 30-day, and in-hospital mortality rate was 19.4%, 23.1%, and 31.0%, respectively. Female (OR = 3.1; 95% CI, 1.4-6.8), liver cirrhosis (OR = 6.2; 95% CI, 1.6-16.6), septic shock (OR = 11.2; 95% CI, 5.1-24.8), and catheter-related infection (OR = 2.6, 95% CI, 1.2-5.8) were the independent risk factors for 30-day mortality. The outcome did not differ according to type of antibiotics used. Among 91 patients with CVC-related BCC bacteremia, delayed CVC removal (> 3 days) had a higher rate of persistent bacteremia (54.5 vs. 26.1%; P = 0.03) and lower rate of clinical response (49.0 vs. 71.9%; P = 0.04), compared with early CVC removal (within 3 days). BCC bacteremia occurring in non-CF patients was mostly hospital-acquired and CVC-related. Early removal of the catheter is crucial in treatment of CVC-related BCC bacteremia.


Assuntos
Bacteriemia/epidemiologia , Infecções por Burkholderia/epidemiologia , Complexo Burkholderia cepacia/isolamento & purificação , Infecções Relacionadas a Cateter/epidemiologia , Fibrose Cística , Idoso , Bacteriemia/tratamento farmacológico , Infecções por Burkholderia/tratamento farmacológico , Infecções por Burkholderia/etiologia , Complexo Burkholderia cepacia/efeitos dos fármacos , Infecções Relacionadas a Cateter/tratamento farmacológico , Infecções Relacionadas a Cateter/etiologia , Feminino , Humanos , Masculino , Testes de Sensibilidade Microbiana , Pessoa de Meia-Idade , República da Coreia/epidemiologia , Estudos Retrospectivos , Combinação Trimetoprima e Sulfametoxazol/farmacologia , Combinação Trimetoprima e Sulfametoxazol/uso terapêutico
9.
BMC Pulm Med ; 20(1): 159, 2020 Jun 05.
Artigo em Inglês | MEDLINE | ID: mdl-32503487

RESUMO

BACKGROUND: Whereas Burkholderia infections are recognized to impair prognosis in cystic fibrosis (CF) patients, there is no recommendation to date for early eradication therapy. The aim of our study was to analyse the current management of initial colonisations with Burkholderia cepacia complex (BCC) or B. gladioli in French CF Centres and its impact on bacterial clearance and clinical outcome. METHODS: We performed a retrospective review of the primary colonisations (PC), defined as newly positive sputum cultures, observed between 2010 and 2018 in five CF Centres. Treatment regimens, microbiological and clinical data were collected. RESULTS: Seventeen patients (14 with BCC, and 3 with B. gladioli) were included. Eradication therapy, using heterogeneous combinations of intravenous, oral or nebulised antibiotics, was attempted in 11 patients. Six out of the 11 treated patients, and 4 out of the 6 untreated patients cleared the bacterium. Though not statistically significant, higher forced expiratory volume in 1 second and forced vital capacity at PC and consistency of treatment with in vitro antibiotic susceptibility tended to be associated with eradication. The management of PC was shown to be heterogeneous, thus impairing the statistical power of our study. Large prospective studies are needed to define whom to treat, when, and how. CONCLUSIONS: Pending these studies, we propose, due to possible spontaneous clearance, to check the presence of Burkholderia 1 month after PC before starting antibiotics, at least in the milder cases, and to evaluate a combination of intravenous beta-lactam + oral or intravenous fluoroquinolone + inhaled aminoglycoside.


Assuntos
Antibacterianos/uso terapêutico , Infecções por Burkholderia/tratamento farmacológico , Complexo Burkholderia cepacia , Fibrose Cística/complicações , Infecções Respiratórias/tratamento farmacológico , Adolescente , Adulto , Infecções por Burkholderia/etiologia , Criança , Fibrose Cística/fisiopatologia , Feminino , Volume Expiratório Forçado , França , Humanos , Masculino , Projetos Piloto , Infecções Respiratórias/etiologia , Estudos Retrospectivos , Prevenção Secundária , Resultado do Tratamento , Adulto Jovem
10.
Am J Infect Control ; 48(2): 199-203, 2020 02.
Artigo em Inglês | MEDLINE | ID: mdl-31345617

RESUMO

BACKGROUND: Contamination of drugs used in minimally invasive treatment may to lead to infection outbreaks and catastrophic public health events that require prompt detection and control. Our aim was to investigate the outbreak of Burkholderia cepacia infection and its source in a tertiary care, general hospital in Beijing, China. METHODS: We investigated the outbreak of B cepacia infection from January 2017 to March 2018. The investigation included a detailed review of all cases, and field investigations. Environmental and product cultures were performed at the microbiology laboratory in the hospital. Isolates were evaluated for molecular relatedness using pulsed-field gel electrophoresis performed in an independent laboratory. RESULTS: In total, 9 patients were infected from November 2017 to March 2018, and all patients had undergone the following surgeries: transurethral resection of the prostate (n = 4), perineal prostate biopsy (n = 2), transurethral resection of bladder tumors (n = 2), and ureteroscopy (n = 1). B cepacia was isolated from the urine of 9 patients, blood of 2 patients, grilles used for puncturing, and 2 samples in 1 batch of analgesic gels. Pulsed-field gel electrophoresis confirmed that the isolates from the patients and gels were homologous. CONCLUSIONS: Our investigation revealed that the outbreak of B cepacia infection was caused by drug contamination.


Assuntos
Anestésicos Locais , Infecções por Burkholderia/etiologia , Burkholderia cepacia/isolamento & purificação , Contaminação de Medicamentos , Sepse/microbiologia , Infecções Urinárias/microbiologia , Idoso , Infecções por Burkholderia/epidemiologia , China/epidemiologia , Surtos de Doenças , Géis , Humanos , Masculino , Pessoa de Meia-Idade , Centros de Atenção Terciária
11.
Microbiol Immunol ; 64(2): 87-98, 2020 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-31769530

RESUMO

Burkholderia cepacia complex (Bcc) are opportunistic pathogens implicated with nosocomial infections, and high rates of morbidity and mortality, especially in individuals with cystic fibrosis (CF). B. cepacia are naturally resistant to different classes of antibiotics, and can subvert the host innate immune responses by producing quorum sensing (QS) controlled virulence factors and biofilms. It still remains a conundrum as to how exactly the bacterium survives the intracellular environment within the host cells of CF patients and immunocompromised individuals although the bacterium can invade human lung epithelial cells, neutrophils, and murine macrophages. The mechanisms associated with intracellular survival in the airway epithelial cells and the role of QS and virulence factors in B. cepacia infections in cystic fibrosis remain largely unclear. The current review focuses on understanding the role of QS-controlled virulence factors and biofilms, and provides additional impetus to understanding the potentials of QS-inhibitory strategies against B. cepacia.


Assuntos
Biofilmes , Infecções por Burkholderia , Burkholderia cepacia/patogenicidade , Fibrose Cística/microbiologia , Percepção de Quorum/imunologia , Animais , Biofilmes/efeitos dos fármacos , Biofilmes/crescimento & desenvolvimento , Infecções por Burkholderia/etiologia , Infecções por Burkholderia/imunologia , Burkholderia cepacia/crescimento & desenvolvimento , Complexo Burkholderia cepacia/patogenicidade , Doenças Transmissíveis Emergentes , Infecção Hospitalar/imunologia , Fibrose Cística/complicações , Fibrose Cística/imunologia , Síndrome da Liberação de Citocina , Farmacorresistência Bacteriana Múltipla , Humanos , Evasão da Resposta Imune , Hospedeiro Imunocomprometido , Inflamação , Lipase/metabolismo , Lipopolissacarídeos/metabolismo , Pulmão/microbiologia , Macrófagos/microbiologia , Metaloendopeptidases/metabolismo , Camundongos , Neutrófilos/imunologia , Sideróforos/metabolismo , Fatores de Virulência/metabolismo
12.
Transpl Infect Dis ; 21(3): e13082, 2019 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-30892778

RESUMO

Burkholderia cepacia complex (Bcc) includes several phenotypically similar but genotypically distinct gram-negative bacteria (GNB) that can colonize the respiratory tract of Cystic Fibrosis (CF) patients. Pathogens are difficult to treat due to intrinsic resistance to multiple antibiotics and are associated to a more rapid decline in lung function and to increased mortality, particularly after lung transplantation. For all these reasons, chronic infection by Burkholderia (B) cenocepacia is presently considered a relative or absolute contraindication in almost all lung transplant centres. We report the case of a young adult CF patient chronically colonized by B multivorans genomovar II, with diabetes and end-stage renal disease treated with renal replacement therapy: a few months after lung transplantation, she developed post-surgery B multivorans bacteremia and multiple brain abscesses. This severe infection did not improve despite multiple standard antibiotic regimen. The introduction of ceftazidime-avibactam, a new ß-lactam/ ß-lactamase inhibitor combination resulted in clinical recovery and in radiological and biochemical improvement.


Assuntos
Compostos Azabicíclicos/uso terapêutico , Abscesso Encefálico/tratamento farmacológico , Infecções por Burkholderia/tratamento farmacológico , Ceftazidima/uso terapêutico , Fibrose Cística/complicações , Transplante de Pulmão/efeitos adversos , Adulto , Antibacterianos/uso terapêutico , Bacteriemia/tratamento farmacológico , Abscesso Encefálico/microbiologia , Infecções por Burkholderia/etiologia , Complexo Burkholderia cepacia/efeitos dos fármacos , Fibrose Cística/microbiologia , Complicações do Diabetes/microbiologia , Combinação de Medicamentos , Quimioterapia Combinada , Feminino , Humanos , Falência Renal Crônica/complicações , Falência Renal Crônica/microbiologia , Pulmão/microbiologia , Pulmão/patologia , Resultado do Tratamento
13.
Clin Infect Dis ; 69(3): 445-449, 2019 07 18.
Artigo em Inglês | MEDLINE | ID: mdl-30346502

RESUMO

BACKGROUND: Burkholderia cepacia complex (Bcc) has caused healthcare-associated outbreaks, often in association with contaminated products. The identification of 4 Bcc bloodstream infections in patients residing at a single skilled nursing facility (SNF) within 1 week led to an epidemiological investigation to identify additional cases and the outbreak source. METHODS: A case was initially defined via a blood culture yielding Bcc in a SNF resident receiving intravenous therapy after 1 August 2016. Multistate notifications were issued to identify additional cases. Public health authorities performed site visits at facilities with cases to conduct chart reviews and identify possible sources. Pulsed-field gel electrophoresis (PFGE) was performed on isolates from cases and suspect products. Facilities involved in manufacturing suspect products were inspected to assess possible root causes. RESULTS: An outbreak of 162 Bcc bloodstream infections across 59 nursing facilities in 5 states occurred during September 2016-January 2017. Isolates from patients and pre-filled saline flush syringes were closely related by PFGE, identifying contaminated flushes as the outbreak source and prompting a nationwide recall. Inspections of facilities at the saline flush manufacturer identified deficiencies that might have led to the failure to sterilize a specific case containing a partial lot of the product. CONCLUSIONS: Communication and coordination among key stakeholders, including healthcare facilities, public health authorities, and state and federal agencies, led to the rapid identification of an outbreak source and likely prevented many additional infections. Effective processes to ensure the sterilization of injectable products are essential to prevent similar outbreaks in the future.


Assuntos
Bacteriemia/epidemiologia , Infecções por Burkholderia/etiologia , Infecção Hospitalar/etiologia , Surtos de Doenças/estatística & dados numéricos , Contaminação de Equipamentos , Seringas/microbiologia , Idoso , Bacteriemia/etiologia , Infecções por Burkholderia/epidemiologia , Complexo Burkholderia cepacia/genética , Infecção Hospitalar/epidemiologia , Infecção Hospitalar/microbiologia , Eletroforese em Gel de Campo Pulsado , Humanos , Solução Salina , Instituições de Cuidados Especializados de Enfermagem , Estados Unidos
14.
Transpl Infect Dis ; 21(2): e13034, 2019 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-30548546

RESUMO

We describe a case of one patient with cystic fibrosis who developed a pan-resistant Burkholderia cepacia complex rapidly progressive bacteraemic pneunonia, following bilateral lung transplantation. The patient was treated with a targeted combination antibiotic therapy (meropenem plus ceftazidime/avibactam plus high doses of nebulized colistimethate sodium). Evolution of the disease was complicated by multiple organ system dysfunction. Finally, clinical improvement and microbiological cure was achieved.


Assuntos
Bacteriemia/microbiologia , Infecções por Burkholderia/diagnóstico , Fibrose Cística/complicações , Transplante de Pulmão/efeitos adversos , Pneumonia Bacteriana/diagnóstico por imagem , Adulto , Antibacterianos/uso terapêutico , Bacteriemia/tratamento farmacológico , Infecções por Burkholderia/tratamento farmacológico , Infecções por Burkholderia/etiologia , Complexo Burkholderia cepacia , Colistina/análogos & derivados , Colistina/uso terapêutico , Fibrose Cística/microbiologia , Farmacorresistência Bacteriana Múltipla , Humanos , Masculino , Pneumonia Bacteriana/tratamento farmacológico , Resultado do Tratamento , Raios X
15.
Int J Mol Sci ; 19(12)2018 Nov 27.
Artigo em Inglês | MEDLINE | ID: mdl-30486355

RESUMO

Cystic fibrosis (CF) is the most life-limiting autosomal recessive disorder in Caucasians. CF is characterized by abnormal viscous secretions that impair the function of several tissues, with chronic bacterial airway infections representing the major cause of early decease of these patients. Pseudomonas aeruginosa and bacteria from the Burkholderia cepacia complex (Bcc) are the leading pathogens of CF patients' airways. A wide array of virulence factors is responsible for the success of infections caused by these bacteria, which have tightly regulated responses to the host environment. Small noncoding RNAs (sRNAs) are major regulatory molecules in these bacteria. Several approaches have been developed to study P. aeruginosa sRNAs, many of which were characterized as being involved in the virulence. On the other hand, the knowledge on Bcc sRNAs remains far behind. The purpose of this review is to update the knowledge on characterized sRNAs involved in P. aeruginosa virulence, as well as to compile data so far achieved on sRNAs from the Bcc and their possible roles on bacteria virulence.


Assuntos
Complexo Burkholderia cepacia/genética , Regulação Bacteriana da Expressão Gênica , Pseudomonas aeruginosa/genética , RNA Bacteriano/genética , Pequeno RNA não Traduzido/genética , Animais , Infecções por Burkholderia/etiologia , Complexo Burkholderia cepacia/patogenicidade , Fibrose Cística/complicações , Fibrose Cística/genética , Humanos , Pneumonia Bacteriana/etiologia , Infecções por Pseudomonas/etiologia , Pseudomonas aeruginosa/patogenicidade , Virulência/genética , Fatores de Virulência/genética
16.
Clinics (Sao Paulo) ; 73: e166, 2018 03 12.
Artigo em Inglês | MEDLINE | ID: mdl-29538493

RESUMO

OBJECTIVES: To evaluate the impact of Burkholderia cepacia complex colonization in cystic fibrosis patients undergoing lung transplantation. METHODS: We prospectively analyzed clinical data and respiratory tract samples (sputum and bronchoalveolar lavage) collected from suppurative lung disease patients between January 2008 and November 2013. We also subtyped different Burkholderia cepacia complex genotypes via DNA sequencing using primers against the recA gene in samples collected between January 2012 and November 2013. RESULTS: From 2008 to 2013, 34 lung transplants were performed on cystic fibrosis patients at our center. Burkholderia cepacia complex was detected in 13 of the 34 (38.2%) patients. Seven of the 13 (53%) strains were subjected to genotype analysis, from which three strains of B. metallica and four strains of B. cenocepacia were identified. The mortality rate was 1/13 (7.6%), and this death was not related to B. cepacia infection. CONCLUSION: The results of our study suggest that colonization by B. cepacia complex and even B. cenocepacia in patients with cystic fibrosis should not be considered an absolute contraindication to lung transplantation in Brazilian centers.


Assuntos
Infecções por Burkholderia/etiologia , Burkholderia cepacia/isolamento & purificação , Fibrose Cística/microbiologia , Transplante de Pulmão/efeitos adversos , Adolescente , Adulto , Brasil/epidemiologia , Infecções por Burkholderia/mortalidade , Contraindicações de Procedimentos , Fibrose Cística/complicações , Fibrose Cística/mortalidade , Fibrose Cística/cirurgia , DNA Bacteriano , Feminino , Humanos , Unidades de Terapia Intensiva , Estimativa de Kaplan-Meier , Tempo de Internação , Transplante de Pulmão/mortalidade , Masculino , Filogenia , Estudos Prospectivos , Análise de Regressão , Fatores de Risco , Fatores de Tempo , Resultado do Tratamento , Adulto Jovem
18.
Clinics ; 73: e166, 2018. tab, graf
Artigo em Inglês | LILACS | ID: biblio-890746

RESUMO

OBJECTIVES: To evaluate the impact of Burkholderia cepacia complex colonization in cystic fibrosis patients undergoing lung transplantation. METHODS: We prospectively analyzed clinical data and respiratory tract samples (sputum and bronchoalveolar lavage) collected from suppurative lung disease patients between January 2008 and November 2013. We also subtyped different Burkholderia cepacia complex genotypes via DNA sequencing using primers against the recA gene in samples collected between January 2012 and November 2013. RESULTS: From 2008 to 2013, 34 lung transplants were performed on cystic fibrosis patients at our center. Burkholderia cepacia complex was detected in 13 of the 34 (38.2%) patients. Seven of the 13 (53%) strains were subjected to genotype analysis, from which three strains of B. metallica and four strains of B. cenocepacia were identified. The mortality rate was 1/13 (7.6%), and this death was not related to B. cepacia infection. CONCLUSION: The results of our study suggest that colonization by B. cepacia complex and even B. cenocepacia in patients with cystic fibrosis should not be considered an absolute contraindication to lung transplantation in Brazilian centers.


Assuntos
Humanos , Masculino , Feminino , Adolescente , Adulto , Adulto Jovem , Transplante de Pulmão/efeitos adversos , Burkholderia cepacia/isolamento & purificação , Infecções por Burkholderia/etiologia , Fibrose Cística/microbiologia , Filogenia , Fatores de Tempo , Brasil/epidemiologia , DNA Bacteriano , Estudos Prospectivos , Análise de Regressão , Fatores de Risco , Transplante de Pulmão/mortalidade , Resultado do Tratamento , Infecções por Burkholderia/mortalidade , Fibrose Cística/cirurgia , Fibrose Cística/complicações , Fibrose Cística/mortalidade , Estimativa de Kaplan-Meier , Contraindicações de Procedimentos , Unidades de Terapia Intensiva , Tempo de Internação
19.
Artigo em Inglês | MEDLINE | ID: mdl-29204272

RESUMO

Effective strategies to manage Burkholderia cepacia complex (Bcc) infections in cystic fibrosis (CF) patients are lacking. We tested combinations of clinically available antibiotics and show that moxifloxacin-ceftazidime could inhibit 16 Bcc clinical isolates at physiologically achievable concentrations. Adding low dose of colistin improved the efficacy of the combo, especially at conditions mimicking CF respiratory secretions.


Assuntos
Antibacterianos/uso terapêutico , Infecções por Burkholderia/tratamento farmacológico , Complexo Burkholderia cepacia/efeitos dos fármacos , Antibacterianos/farmacologia , Infecções por Burkholderia/etiologia , Infecções por Burkholderia/microbiologia , Complexo Burkholderia cepacia/isolamento & purificação , Fibrose Cística/complicações , Quimioterapia Combinada , Humanos , Testes de Sensibilidade Microbiana , Infecções Respiratórias/tratamento farmacológico , Infecções Respiratórias/etiologia
20.
J Popul Ther Clin Pharmacol ; 24(1): 40-45, 2017 01 30.
Artigo em Inglês | MEDLINE | ID: mdl-28186714

RESUMO

Children with cystic fibrosis are commonly colonized with multi-resistant bacteria. In such patients, infectious exacerbation may require salvage therapy with uncommonly used antimicrobials, including chloramphenicol. Chloramphenicol is rarely used nowadays because of the associated severe adverse events. We describe the case of a 15-year-old female with terminal cystic fibrosis who required intravenous (IV) chloramphenicol treatment for a Burkholderia cepacia (B. cepacia) exacerbation. The child subsequently developed lactic acidosis and secondary respiratory compensation adding to her baseline respiratory distress. Based on the Naranjo scale, the probability of chloramphenicol being the cause of the hyperlactatemia and associated respiratory distress was rated as probable, as the adverse effects resolved upon discontinuation of the drug. Subsequent genotyping for mitochondrial polymorphism (G3010A) confirmed a possible susceptibility to lactic acidosis from mitochondrial RNA-inhibiting agents such as chloramphenicol. Hyperlactatemia is a rare but life threatening adverse effect that has been previously reported with chloramphenicol exposure, but is not generally thought of. Clinicians should be aware of this potentially life threatening, but reversible adverse event. Lactate should be monitored under chloramphenicol and it should be discontinued as soon as this complication is suspected, especially in patients with low respiratory reserve.


Assuntos
Acidose Láctica/induzido quimicamente , Infecções por Burkholderia/tratamento farmacológico , Infecções por Burkholderia/etiologia , Cloranfenicol/efeitos adversos , Fibrose Cística/complicações , Acidose Láctica/genética , Adolescente , Burkholderia cepacia , Cloranfenicol/uso terapêutico , Feminino , Genótipo , Humanos , RNA/antagonistas & inibidores , RNA Mitocondrial
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...